 TEL AVIV, Israel, Aug. 30, 2021 GLOBE NEWSWIRE -- VBL Therapeutics NASDAQ: VBLT today announced enrollment of new patients in VB-111 studies in the Unites States will resume immediately following authorization by the U.S. Food and Drug Administration FDA Chemistry, Manufacturing and Controls CMC Group to use new batches of ofranergene obadenovec VB-111 produced in VBLs commercial-scale GMP Modiin, Israel facility in clinical studies in the United States. 